GlassScriptPhysician profile
Anthony J Brune
NPI 1528403169
$18,594.75
in general payments reported to CMS, 2019-2025
35 companies · $480 in 2025
The $480 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $9,936 · 2021: $600 · 2022: $6,094 · 2023: $863 · 2024: $358 · 2025: $480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,251 · Honoraria: $450.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,250.75 |
| Honoraria | $450.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $8,275.03 | 2019-2023 | Soliris, Ultomiris |
| Horizon Therapeutics Plc | $6,236.99 | 2022-2023 | Uplizna |
| Genentech USA, INC. | $2,272.68 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Abbvie INC. | $351.75 | 2023-2025 | Ubrelvy, Botox, Qulipta |
| Genzyme Corporation | $191.60 | 2019-2022 | |
| Biogen, INC. | $188.06 | 2019-2025 | Tysabri, Spinraza, Skyclarys |
| Novartis Pharmaceuticals Corporation | $103.57 | 2019-2025 | |
| Catalyst Pharmaceuticals, INC. | $85.67 | 2020-2025 | |
| Ucb, INC. | $76.32 | 2019-2024 | Briviact |
| Teva Pharmaceuticals USA, INC. | $75.65 | 2020-2025 | Ajovy, Austedo Xr |
| Lilly USA, LLC | $63.37 | 2020-2025 | Amyvid, Emgality, Kisunla |
| Pfizer INC. | $61.41 | 2025 | |
| Axsome Therapeutics, INC. | $55.65 | 2023-2025 | Sunosi, Symbravo |
| Merz Pharmaceuticals, LLC | $52.22 | 2023-2024 | Xeomin |
| Lundbeck LLC | $42.76 | 2022-2023 | Vyepti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $42.24 | 2020 | |
| Acadia Pharmaceuticals INC | $37.78 | 2022 | |
| Avanir Pharmaceuticals, INC. | $34.92 | 2020 | |
| Amgen INC. | $30.64 | 2022-2025 | Tepezza |
| Neurocrine Biosciences, INC. | $29.02 | 2025 | |
| Acorda Therapeutics, INC | $26.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.05 | 2025 | Hyqvia |
| Sk Life Science, INC. | $23.55 | 2025 | |
| Argenx US, INC. | $23.15 | 2024 | Vyvgart Hytrulo |
| Grifols USA, LLC | $23.09 | 2020 | |
| Tanabe Pharma America, INC. | $20.30 | 2024 | |
| Emd Serono, INC. | $18.95 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $18.14 | 2023 | Rexulti |
| Sage Therapeutics, LLC | $17.87 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.55 | 2022 | |
| Allergan, INC. | $16.14 | 2022 | |
| Aucta Pharmaceuticals, INC. | $15.37 | 2025 | Motpoly Xr |
| Averitas Pharma INC. | $14.18 | 2024 | Qutenza |
| Corium, LLC | $13.90 | 2022 | |
| Eisai INC. | $13.21 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Brune listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.